Meenakshi Sharma

Meenakshi Sharma

Auto-generated profile, based on publicly available information

Meenakshi Sharma

University Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Panjab University, Chandigarh -160014, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Parasitology International
Verified
Journal Article
Closed access
SKSukhbir Kaur
Sukhbir Kaur
HSHeena Sachdeva
Heena Sachdeva
SDShivani Dhuria
Shivani Dhuria
MSMeenakshi Sharma
Meenakshi Sharma
TKTejinder Kaur
Tejinder Kaur

1 May 2012 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MSMeenakshi Sharma
Meenakshi Sharma
RSRakesh Sehgal
Rakesh Sehgal
SKSukhbir Kaur
Sukhbir Kaur
Most available drugs against visceral leishmaniasis are toxic, and growing limitations in available chemotherapeutic strategies due to emerging resistant strains and lack of an effective vaccine against visceral leishmaniasis deepens the crisis. Antineoplastic drugs like miltefosine have in the past been effective against the parasitic infections. An antineoplastic drug, cisplatin (cis-diamminedichloroplatinum II; CDDP), is recognized as a DNA-damaging drug which also induces alteration of cell-cycle in both promastigotes and amastigotes leading to cell death. First in vivo reports from our laboratory revealed the leishmanicidal potential of cisplatin. However, high doses of cisplatin produce impairment of kidney, which can be reduced by the administration of antioxidants. The present study was designed to evaluate the antileishmanial effect of cisplatin at higher doses (5 mg and 2.5 mg/kg body weight) and its combination with different antioxidants (vitamin C, vitamin E and silibinin) so as to eliminate the parasite completely and reduce the toxicity. In addition, various immunological, hematological and biochemical changes induced by it in uninfected and Leishmania donovani infected BALB/c mice were investigated. A significant reduction in parasite load, higher IgG2a and lower IgG1 levels, enhanced DTH responses, and greater concentration of Th1 cytokines (IFN-γ, IL-2) with a concomitant down regulation of IL-10 and IL-4 pointed towards the generation of the protective Th1 type of immune response. A combination of cisplatin with antioxidants resulted in successful reduction of nephrotoxicity by normalizing the enzymatic levels of various liver and kidney function tests. Reduction in parasite load, increase in Th1 type of immune responses, and normalization of various biochemical parameters occurred in animals treated with cisplatin in combination with various antioxidants as compared to those treated with the drug only. The above results are promising as antioxidants reduced the potential toxicity of high doses of cisplatin, making the combination a potential anti-leishmanial therapy, especially in resistant cases. Leishmaniasis, a neglected tropical disease (NTD) caused by Leishmania, has been put on the World Health Organization agenda for eradication as a part of their Special Programme for Tropical Diseases Research. Visceral leishmaniasis (VL) is a life-threatening disease when no treatment is given. Most of the drugs still used to treat VL are often expensive, difficult to administer, have serious side effects, and several are becoming ineffective because of increasing parasite resistance. Cisplatin is a first-generation platinum-containing drug, used in the treatment of various solid tumors. We have for the first time characterized the in vivo effect of cisplatin in murine experimental visceral leishmaniasis, but at higher doses it is nephrotoxic. Considering the above findings, the present study was designed to evaluate the protective efficacy of the drug in combination with various antioxidants to reduce or prevent cisplatin-induced nephrotoxicity. Drug treatment induces a higher secretion of Th1 cytokines, diminution in parasite burden, and the supplementation of antioxidants which are antagonists of the toxicity helps in reducing the nephrotoxicity.

1 December 2009 in Parasitology International
Verified
Journal Article
Closed access
RNRajeev Nagill
Rajeev Nagill
RMRaman Mahajan
Raman Mahajan
MSMeenakshi Sharma
Meenakshi Sharma
SKSukhbir Kaur
Sukhbir Kaur

17 August 2017 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MSMeenakshi Sharma
Meenakshi Sharma
RCRenu Chadha
Renu Chadha
NDNeelima Dhingra
Neelima Dhingra
Background: Benign prostatic hyperplasia (BPH), the most common condition in aging men is the non cancerous proliferation of epithelial and stromal cells of the prostate gland and is associated with lower urinary tract symptoms (LUTS) such as frequency hesitancy urgency etc. Sources of symptoms in patient with BPH appear to be both static and dynamic component. Better understanding of the prostate physiology, function and pathogenesis has lead to the development of promising agents, useful in the management of lower urinary tract symptoms in men. Objective: Treatment of clinical BPH aims to improve symptoms, prevent urinary tract infections, avoid renal insult, relief obstruction and improve bladder emptying. Many herbal formulations, or plant derived non-nutritive compounds with protective or disease preventive properties are getting popularized worldwide for the management of BPH, especially due to long term side effects of pharmacological treatment and risk of mortality associated with surgical procedures. Phytotherapeutic preparations are plant extracts with different components obtained by different extraction procedures. Numerous mechanisms of action have been postulated for mono and combination plant extracts. Conclusion: This article give a brief account of rationale and efficacy of various existing phytotherapeutic agents in the management of benign prostatic hyperplasia, including the herbs which hold the potential promise are also mentioned, although much research is still required.

1 January 2013 in Journal of Interdisciplinary Histopathology
Verified
Journal Article
Closed access
PDF file
MSMeenakshi Sharma
Meenakshi Sharma
SKSukhbir Kaur
Sukhbir Kaur
Objective: Therapeutic interventions against visceral leishmaniasis (VL) are limited and facing serious concerns of toxicity, high cost and emerging resistance, there is a greater interest in new drug developments which are cost effective, efficient and easily available to people suffering from leishmaniasis. Cisplatin (cis-diamminedichloroplatinum II; CDDP) has been found to have antileishmanial activity in vitro and in vivo which lead towards an apoptosis like cell death of both promastigotes and amastigotes and a significant reduction in parasite load and enhanced DTH responses which suggested the generation of protective cell-mediated immune responses. But, at higher doses it causes nephrotoxicity-a major side effect. The present study was designed to evaluate the protective efficacy of antioxidants on cisplatin induced tissue damage in Leishmania donovani infected BALB/c mice. Materials and methods: L. donovani infected and uninfected animals were treated with higher doses (5 and 2.5 mg/kg body weight) of cisplatin alone and in combination with antioxidants (vitamin C, vitamin E and silibinin) for 5 days. Mice were examined for the protective effects of antioxidants on cisplatin indiced tissue damage by DNA fragmentation and histological studies of kidneys, liver and spleen. Results: The damage caused by cisplatin was ameliorated after the supplementation of antioxidants showing a marked reduction in the extent of tubular damage, the focal reaction changes in liver were reversed and no signs of toxicity in the spleen were reported. Moreover, no DNA damage was observed in animals treated with cisplatin along with various antioxidants. Conclusion: The present results showed that antioxidants helped in the amelioration of drug induced toxic effects against murine visceral leishmaniasis, making the combination a potential anti-leishmanial therapy. [J Interdiscipl Histopathol 2013; 1(3.000): 121-136